logo
Most common pain reliever taken by 100million Americans may make you more likely to cheat and do drugs

Most common pain reliever taken by 100million Americans may make you more likely to cheat and do drugs

Daily Mail​4 days ago
The world's most popular pain reliever may cause people to take more risks and reduce fear around risky decisions, leading to bolder behavior.
Nearly a quarter of Americans take acetaminophen - the active ingredient in Tylenol - weekly and data estimates 100million Americans take it annually.
Recently, scientists have been investigating how it might influence people's behavior on a larger scale.
To measure the effects of acetaminophen, researchers from Ohio State University had over 500 college students participate in a risk-taking game.
Some participants received a normal dose of acetaminophen, 1,000 mg, mirroring standard over-the-counter use, while others received a placebo.
In the game, they inflated a virtual balloon to earn cash rewards. If it burst, they lost everything. The acetaminophen group pumped more aggressively and popped more balloons, suggesting they cared less about the risk of losing.
In follow-up surveys, those on acetaminophen rated activities like bungee jumping or gambling as less risky than the placebo group, but only when the scenarios were emotionally charged.
Researchers warned that while the changes in risk-taking are subtle, they're worth watching, mainly because acetaminophen is found in over 600 medications.
The study suggested that acetaminophen's effect on risk-taking behavior likely goes beyond just dulling fear.
The over-the-counter drug may also alter deeper cognitive and neurological processes, including by turning off the brain's alarm signals for danger.
It may also reduce awareness of one's mistakes, and quiet a part of the brain that gives someone a gut feeling that danger is close.
Dr Baldwin Way, co-author of the 2020 study and associate professor of psychology at Ohio State University, said: 'Acetaminophen seems to make people feel less negative emotion when they consider risky activities – they just don't feel as scared.'
Dr Way conducted three experiments in his report, published in the journal Social Cognitive and Affective Neuroscience.
Across these studies, 545 undergraduate students took part in a task developed in 2002 that is often used by researchers to measure risk-taking behavior: inflating a balloon in exchange for cash rewards.
They can stop at any time, bank the money, and move on to the next balloon.
The people who took acetaminophen pumped more and more, despite the risk of the balloon popping and losing all their money.
In the balloon-popping game, people who took acetaminophen pumped 32 times compared to 29 times in the placebo group, and had more bursts, with 8.5 in the acetaminophen group compared to 7.9 in the placebo group.
Dr Way said: 'If you're risk-averse, you may pump a few times and then decide to cash out because you don't want the balloon to burst and lose your money.
'But for those who are on acetaminophen, as the balloon gets bigger, we believe they have less anxiety and less negative emotion about how big the balloon is getting and the possibility of it bursting.'
Previous research by Dr Way on the effects of acetaminophen on people's behavior has suggested that it dulls positive and negative emotions, including hurt feelings, distress over another person's suffering, and their joy.
He posited in his latest research that the medicine reduces anticipatory anxiety. Typically, as the balloon expands, people feel growing anxiety about it bursting, making them stop pumping earlier.
The drug may blunt this nervous feeling, though, causing people to take more risks.
And according to Dr Way, 'increased risk-taking could have important effects on society.'
With a dampened feeling of fear, anxiety and negative emotions, people may be more likely to partake in risky behavior, including cheating on partners, drinking excessively and taking drugs.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sorry America, but it's not Australia's fault that your healthcare system is failing you
Sorry America, but it's not Australia's fault that your healthcare system is failing you

The Guardian

timea day ago

  • The Guardian

Sorry America, but it's not Australia's fault that your healthcare system is failing you

If I were president of the United States, I would certainly be concerned about the cost and performance of the country's healthcare system. The grim statistics are well known. As of 2022, the US spent $12,555 per person on healthcare, almost twice as much as other wealthy countries, including Australia. That gap alone cancels out about half of the difference in income per person between the US and Australia, according to World Bank estimates. Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries. This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes. Sign up: AU Breaking News email And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic. There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse. It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US. The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists. And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US. This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe. More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector. But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory. The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange. John Quiggin is a professor at the University of Queensland's school of economics

Trump will bring back push up, mile run test for school kids
Trump will bring back push up, mile run test for school kids

The Herald Scotland

timea day ago

  • The Herald Scotland

Trump will bring back push up, mile run test for school kids

Counting push ups in the gym. On July 31, President Donald Trump will sign an executive order that reestablishes the Presidential Fitness Test for teens and preteens in America's public schools, said White House Press Secretary Karoline Leavitt. The fitness test requires students to complete a range of physical challenges ranging from sit-ups to pull-ups. "MAKE AMERICA FIT AGAIN!" Leavitt wrote in a post on X. The Presidential Fitness Test was a part of American physical education classes from the time it was first initiated by President Dwight Eisenhower in 1956 to the 2012-2013 school year. That's when President Barack Obama replaced it with a program designed to focus on long-term student health over physical performance. Donald Trump invites athletes To White House as he reinstates Presidential Fitness Test What does Trump's order say? The executive order says the Trump administration is reintroducing the test in the nation's public schools because of the high rates of obesity and chronic disease in the United States. Trump directed Secretary of Health and Human Services Robert F. Kennedy Jr. to renew the test. The president also reestablished the President's Council on Sports, Fitness and Nutrition, formerly known as the President's Council on Youth Fitness, created by Eisenhower in 1956. The White House called the move an attempt "to develop bold and innovative fitness goals for young Americans with the aim of fostering a new generation of healthy, active citizens." Trump directed the reestablished council to create school-based programs that "reward excellence in physical education and develop criteria for a Presidential Fitness Award" in his order. "This Order ensures American youth will have opportunities at the global, national, State, and local levels that emphasize the importance of an active lifestyle, good nutrition, American sports, and military readiness," the White House said in a statement to USA TODAY. Why did the Presidential Fitness Test go away? The Obama administration replaced the Presidential Fitness Test with the Presidential Youth Fitness Program to shift the focus on physical fitness in schools away from student performance and toward students' overall health as they grow into adulthood. "The program minimizes comparisons between children and instead supports students as they pursue personal fitness goals for lifelong health," reads a previous description of the program from the Department of Health and Human Services website. Paul Roetert, former chief executive officer of the Society of Health and Physical Educators, said at the time that it was implemented "to keep fitness in a positive mode," Education Week reported in 2012."Children's individual fitness scores will not be used as a criteria for grading in physical education class and will be confidential between the teacher, student and parent," Roetert said. Nancy Brown, chief executive officer of the American Heart Association, also supported the change when it was implemented more than a decade ago, the news outlet reported. "This assessment will be a great way to evaluate the health impact of physical education programs in schools and allow for a standardized comparison of fitness levels of children across the country," Brown said. Contact Kayla Jimenez at kjimenez@ Follow her on X at @kaylajjimenez.

Sorry America, but it's not Australia's fault that your healthcare system is failing you
Sorry America, but it's not Australia's fault that your healthcare system is failing you

The Guardian

timea day ago

  • The Guardian

Sorry America, but it's not Australia's fault that your healthcare system is failing you

If I were president of the United States, I would certainly be concerned about the cost and performance of the country's healthcare system. The grim statistics are well known. As of 2022, the US spent $12,555 per person on healthcare, almost twice as much as other wealthy countries, including Australia. That gap alone cancels out about half of the difference in income per person between the US and Australia, according to World Bank estimates. Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries. This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes. Sign up: AU Breaking News email And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic. There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse. It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US. The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists. And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US. This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe. More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector. But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory. The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange. John Quiggin is a professor at the University of Queensland's school of economics

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store